The current data also allowed us to examine the associations of CSF Ng levels with two other key biomarkers for AD: hippocampal atrophy measured by volumetric MRI and cortical glucose metabolism assessed by FDG-PET. This evidence concerns the gene NRGN and hippocampal atrophy.